Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesDermatologyCigna Vtama Quantity Limits Policy Update | OpenPa…
    Ask Trek AI about this page
    CurrentCignaPolicy DQM024

    Dermatology - Vtama Drug Quantity Management Policy - Per Days

    Customize your policy alerts

    Sign up for Cigna Policy DQM024 alerts

    Get alerted when Policy DQM024 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines quantity limits and exception criteria for coverage of Vtama topical cream for Cigna-administered health benefit plans, affecting prescribers and pharmacy prior authorization processes.

    Policy Summary
    PayerCigna
    PolicyDermatology - Vtama Drug Quantity Management Policy - Per Days
    Policy CodePolicy DQM024
    Change TypeMinor/no material change
    Effective DateAug 15, 2026
    Last ReviewAug 15, 2026
    Next Review DateJun 18, 2026
    Key ActionProvide documentation demonstrating medical necessity for quantities above standard limits; approvals are valid for 1 year.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    60 gstandard tube size / retail 30-day maximum
    180 ghome delivery 90-day maximum
    8%BSA coverage per 60 g per 30 days (approx.)
    360 gmax retail per 30 days with exception
    1080 gmax home delivery per 90 days with exception

    Coverage Criteria and Exceptions

    Quantity Limit Exception

    Exceptions to the standard quantity limits are covered as medically necessary when the following is met:

    Exception for treating >8% BSA: If a patient needs to treat greater than 8% of their body surface area, approve the requested quantity, not to exceed 360 grams (6 tubes) per 30 days at retail and 1080 grams (18 tubes) per 90 days at home delivery.>8% BSA; max 360 g/30 days retail; max 1080 g/90 days home delivery

    Any other exception is considered not medically necessary.

    Any exception to the listed quantity limits that does not meet the stated criteria is considered not medically necessary. Specifically, exceptions are only covered when the documented clinical situation meets the criteria described for increased quantity (see criteria below).

    Requests for quantities exceeding the stated maxima are considered not medically necessary unless they meet the exception criteria. The standard maximums are 60 g per 30 days (retail) and 180 g per 90 days (home delivery); the allowable exception limits are 360 g per 30 days (retail) and 1080 g per 90 days (home delivery) when the criteria are met. Any request that exceeds these exception maxima or is not justified by treatment of >8% BSA should be denied as not medically necessary.

    Policy Summary
    PayerCigna
    PolicyDermatology - Vtama Drug Quantity Management Policy - Per Days
    Policy CodePolicy DQM024
    Change TypeMinor/no material change
    Effective DateAug 15, 2026
    Last ReviewAug 15, 2026
    Next Review DateJun 18, 2026
    Key ActionProvide documentation demonstrating medical necessity for quantities above standard limits; approvals are valid for 1 year.
    SourceLink
    On This Page
    Coverage Criteria and ExceptionsProduct Coding and Quantity AssumptionsProvider Actions, Prior Authorization, and DocumentationBackgroundDefinitions

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Product Coding and Quantity Assumptions

    Product / NDC descriptiveNDC
    tapinarof 1% creamVtama topical cream, 60 g tube
    BSA coverage and quantity thresholds
    Assumed BSA coverage per 60 g (30 days)Approximately 8% body surface area per 60 g when applied once daily for 30 days (based on FTU estimates).
    Standard retail 30-day quantity60 g per 30 days (one 60 g tube).
    Exception — retail maximum per 30 daysUp to 360 g (6 tubes) per 30 days when treating >8% BSA and meeting criteria.
    Exception — home delivery maximum per 90 daysUp to 1080 g (18 tubes) per 90 days when treating >8% BSA and meeting criteria.

    Provider Actions, Prior Authorization, and Documentation

    Prior Authorization

    Quantity management / prior authorization overview

    Quantity management is enforced at the point of service; exceptions to standard quantity limits require meeting the clinical criteria described in the policy and approvals are valid for 1 year.

    • Standard retail maximum: 60 g per 30 days (one 60 g tube).
    • Standard home delivery maximum: 180 g per 90 days (three 60 g tubes).
    • Exceptions covered only when criteria for treating >8% BSA are met (see criteria).
    • Meeting quantity management criteria does not satisfy other prior authorization or medical necessity requirements.
    Step Therapy

    No step therapy specified

    This policy does not specify any step therapy requirements for Vtama.

    Documentation Required

    Documentation required for quantity exceptions

    Provide documentation demonstrating medical necessity to justify quantities above the standard limits; all approvals are issued for 1 year and meeting quantity criteria does not remove other prior authorization or medical necessity obligations.

    • Documentation should support treatment of >8% body surface area when requesting quantities above standard maxima.
    • Approvals granted under this Drug Quantity Management program are valid for one year.
    Denial Risk

    Point-of-service adjudication and denial risk

    If the Drug Quantity Management rule is not met at point of service, coverage will be determined by the policy Criteria below; failure to meet those criteria may result in denial.

    • Criteria allow exceptions only when treating >8% BSA and within maximums of 360 g/30 days retail or 1080 g/90 days home delivery.
    • Requests exceeding those maxima or not justified by >8% BSA are considered not medically necessary.

    Background

    Vtama (tapinarof 1% cream) is supplied as a 60 gram tube. Quantity limits are based on this tube size with a standard dispensing allowance of 60 g per 30 days (one tube) and a home delivery allowance of 180 g per 90 days (three tubes). Clinical trials enrolled patients with mean body surface area involvement consistent with these assumptions; when a patient requires treatment of greater than 8% BSA, an exception may be approved up to 360 g per 30 days (6 tubes retail) or 1080 g per 90 days (18 tubes home delivery) as described in the criteria.

    Definitions

    Finger‑tip unit (FTU) — topical dosing reference
    Definition (FTU)One finger‑tip unit (FTU) is the amount squeezed from a standard tube along an adult fingertip, ≈0.5 g.
    Area treated per FTUOne FTU treats an area approximately twice the size of an adult hand (~2% BSA).
    Application implicationUsing the FTU method, 2 g (≈4 FTUs) provides enough product for one application to ~8% BSA.